Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).

• Status: Completed
• Trial end date: 2005-02-01

Summary

Study to assess the effects of adding tegaserod to PPI therapy results in clinically meaningful improvement of GERD symptoms in patients with incomplete relief of symptoms on daily PPI therapy alone.

• Phase: Phase 3

Details

• Lead Sponsor: Novartis
• Treatments: Proton Pump Inhibitors; Tegaserod